{"slideshow_credits": null, "snippet": "The British drug maker said it was examining \u201cpotential strategic options\u201d with Aceta Pharma, a cancer-drug developer with operations in the Netherlands and California.", "abstract": "British drug maker AstraZeneca says it is exploring merger options with Acerta Pharma.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Chad", "role": "reported", "lastname": "BRAY", "rank": 1, "organization": ""}], "original": "By CHAD BRAY"}, "web_url": "http://www.nytimes.com/2015/12/15/business/dealbook/astrazeneca-acerta-pharma-talks.html", "lead_paragraph": "The British drug maker said it was examining \u201cpotential strategic options\u201d with Aceta Pharma, a cancer-drug developer with operations in the Netherlands and California.", "headline": {"main": "AstraZeneca Exploring \u2018Strategic Options\u2019 With Acerta Pharma", "print_headline": "Business Briefing; AstraZeneca Is Exploring Its Options With Acerta"}, "_id": "566e942038f0d83e10be15cc", "word_count": "212", "multimedia": [{"height": 126, "url": "images/2015/12/15/business/db-astrazeneca-web1/db-astrazeneca-web1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/12/15/business/db-astrazeneca-web1/db-astrazeneca-web1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2015/12/15/business/db-astrazeneca-web1/db-astrazeneca-web1-articleLarge.jpg", "legacy": {"xlarge": "images/2015/12/15/business/db-astrazeneca-web1/db-astrazeneca-web1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/12/15/business/db-astrazeneca-web1/db-astrazeneca-web1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/12/15/business/db-astrazeneca-web1/db-astrazeneca-web1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-12-15T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Acerta Pharma BV", "is_major": "N", "rank": "1"}, {"name": "organizations", "value": "AstraZeneca PLC", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Cancer", "is_major": "N", "rank": "5"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}